Seeking Alpha·Aug 6, 2026
Cardlytics, Inc. (CDLX) Q2 2026 Earnings Call TranscriptCardlytics, Inc. (CDLX) Q2 2026 Earnings Call Transcript
Cardlytics faces a precarious outlook as its core advertising network experiences a severe 44.6% revenue decline in 2026Q1, signaling potential structural obsolescence in its intermediary model. The company's inability to scale fixed costs, evidenced by a -24....
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$1.50+34.8% vs -$2.30 | $37M-0.3% vs $37M |
Q2 2026 May 7, 2026 | -$0.80+78.4% vs -$3.70 | $34M-7.7% vs $37M |
Q2 2026 Mar 4, 2026 | -$0.15+27.4% vs -$0.21 | $56M+3.0% vs $54M |
Q4 2025 Nov 5, 2025 | -$1.36-316.3% vs -$0.33 | $52M-4.6% vs $55M |
Cardlytics, Inc. (CDLX) Q2 2026 Earnings Call Transcript
ATLANTA--(BUSINESS WIRE)--Cardlytics, Inc. (NASDAQ: CDLX), a purchase intelligence platform, today announced financial results for the second quarter ended June 30, 2026. "The second quarter shows that our execution is translating directly into results. We were within our guidance across all key metrics, with margins improving every single month of the quarter,” said Amit Gupta, CEO of Cardlytics. “We added new advertiser relationships and deepened our partnerships with existing financial insti.
ATLANTA--(BUSINESS WIRE)--Cardlytics, Inc. (NASDAQ: CDLX) announced that on Aug. 3, 2026, Cardlytics granted an aggregate of 50,000 restricted stock units of Cardlytics to its newly appointed Chief Legal Officer, Chris Cheng. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”). The restricted stock units shall v.
ATLANTA--(BUSINESS WIRE)--Cardlytics, Inc. (NASDAQ: CDLX) today announced that on July 29, 2026, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 10,320 restricted stock units of Cardlytics to 10 newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”). For a.
Benchmark CDLX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cardlytics, Inc. (CDLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.44 | $19.98M | -0.18 | -16.18% | -44.36% | -326.02% | — | |
| $8.64 | $356.86M | -45.47 | -11.71% | -2.95% | -1.95% | — | |
| $24.06 | $3.45B | 25.33 | 6.85% | 22.49% | 18.62% | — | |
| $11.54 | $1.4B | -34.97 | 15.24% | -4.46% | -14.77% | — | |
| $80.67 | $5.17B | 58.88 | 15.24% | 14.48% | 7.24% | — | |
| $10.34 | $1.74B | 44.96 | 11.75% | 7.91% | 4.43% | — |
Cardlytics, Inc. (CDLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cardlytics, Inc. (CDLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
May 20, 2026·SEC
May 12, 2026·SEC
Get notified when CDLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cardlytics, Inc. (CDLX) stock FAQ — growth, dividends, profitability & financials explained
Cardlytics, Inc. (CDLX) reported $179.3M in revenue for fiscal year 2025. This represents a 131% increase from $77.6M in 2015.
Cardlytics, Inc. (CDLX) saw revenue decline by 16.2% over the past year.
Cardlytics, Inc. (CDLX) reported a net loss of $100.3M for fiscal year 2025.
Cardlytics, Inc. (CDLX) has a return on equity (ROE) of -326.0%. Negative ROE indicates the company is unprofitable.
Cardlytics, Inc. (CDLX) had negative free cash flow of $4.0M in fiscal year 2025, likely due to heavy capital investments.
